UroGen Pharma Statistics

Total Valuation

UroGen Pharma has a market cap or net worth of EUR 1.15 billion. The enterprise value is 1.15 billion.

Market Cap	1.15B
Enterprise Value	1.15B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	46.81M
Shares Outstanding	n/a
Shares Change (YoY)	+18.43%
Shares Change (QoQ)	+0.67%
Owned by Insiders (%)	2.09%
Owned by Institutions (%)	80.49%
Float	37.07M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.93
PB Ratio	-11.65
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8.18
EV / Sales	13.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.75

Financial Position

The company has a current ratio of 3.99

Current Ratio	3.99
Quick Ratio	3.47
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.94
Interest Coverage	-8.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-33.96%
Return on Invested Capital (ROIC)	-101.59%
Return on Capital Employed (ROCE)	-92.65%
Revenue Per Employee	286,622
Profits Per Employee	-488,935
Employee Count	235
Asset Turnover	0.40
Inventory Turnover	1.46

Taxes

In the past 12 months, UroGen Pharma has paid 2.56 million in taxes.

Income Tax	2.56M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +53.37% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+53.37%
50-Day Moving Average	17.20
200-Day Moving Average	13.84
Relative Strength Index (RSI)	76.00
Average Volume (20 Days)	10

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.48

Income Statement

In the last 12 months, UroGen Pharma had revenue of EUR 82.26 million and -140.32 million in losses. Loss per share was -2.95.

Revenue	82.26M
Gross Profit	72.35M
Operating Income	-112.76M
Pretax Income	-137.77M
Net Income	-140.32M
EBITDA	-111.74M
EBIT	-112.76M
Loss Per Share	-2.95

Full Income Statement

Balance Sheet

The company has 108.27 million in cash and 110.75 million in debt, giving a net cash position of -2.15 million.

Cash & Cash Equivalents	108.27M
Total Debt	110.75M
Net Cash	-2.15M
Net Cash Per Share	n/a
Equity (Book Value)	-98.36M
Book Value Per Share	-2.10
Working Capital	107.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -117.39 million and capital expenditures -329,840, giving a free cash flow of -117.72 million.

Operating Cash Flow	-117.39M
Capital Expenditures	-329,840
Free Cash Flow	-117.72M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 87.95%, with operating and profit margins of -137.08% and -170.59%.

Gross Margin	87.95%
Operating Margin	-137.08%
Pretax Margin	-167.47%
Profit Margin	-170.59%
EBITDA Margin	-135.84%
EBIT Margin	-137.08%
FCF Margin	n/a

Dividends & Yields

UroGen Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-18.43%
Shareholder Yield	-18.43%
Earnings Yield	-12.25%
FCF Yield	-10.27%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

UroGen Pharma has an Altman Z-Score of -6.96 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.96
Piotroski F-Score	2